SIGA Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)

SIGA Technologies, Inc. (NASDAQ:SIGAGet Rating) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 1,200 call options on the company. This represents an increase of 1,438% compared to the typical volume of 78 call options.

SIGA Technologies Price Performance

Shares of SIGA opened at $10.86 on Thursday. The company has a market cap of $793.04 million, a PE ratio of 11.31 and a beta of 0.67. SIGA Technologies has a one year low of $5.84 and a one year high of $26.99. The stock has a 50-day moving average of $17.31 and a 200-day moving average of $11.91.

SIGA Technologies (NASDAQ:SIGAGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $0.03 EPS for the quarter. SIGA Technologies had a net margin of 48.67% and a return on equity of 48.79%. The company had revenue of $16.67 million for the quarter. Analysts expect that SIGA Technologies will post 0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG raised its stake in shares of SIGA Technologies by 30.3% during the second quarter. UBS Group AG now owns 4,596 shares of the company’s stock valued at $53,000 after acquiring an additional 1,070 shares during the last quarter. Amalgamated Bank purchased a new stake in shares of SIGA Technologies during the first quarter valued at approximately $56,000. Qube Research & Technologies Ltd purchased a new stake in shares of SIGA Technologies during the fourth quarter valued at approximately $82,000. Lazard Asset Management LLC grew its holdings in shares of SIGA Technologies by 3,193.2% during the first quarter. Lazard Asset Management LLC now owns 16,005 shares of the company’s stock valued at $113,000 after buying an additional 15,519 shares during the last quarter. Finally, Bank of Nova Scotia purchased a new stake in SIGA Technologies in the second quarter worth approximately $126,000. 42.55% of the stock is currently owned by hedge funds and other institutional investors.

About SIGA Technologies

(Get Rating)

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.

Read More

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with's FREE daily email newsletter.